Ying Huang
Stock Analyst at B of A Securities
(2.40)
# 2,525
Out of 5,241 analysts
39
Total ratings
53.33%
Success rate
9.66%
Average return
Main Sectors:
Stocks Rated by Ying Huang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $571 → $598 | $434.31 | +37.69% | 15 | Mar 10, 2026 | |
| GILD Gilead Sciences | Maintains: Neutral | $70 → $72 | $130.50 | -44.83% | 8 | Feb 5, 2020 | |
| RGNX REGENXBIO | Downgrades: Neutral | $64 → $80 | $5.66 | +1,313.43% | 3 | Jul 23, 2018 | |
| ESPR Esperion Therapeutics | Downgrades: Underperform | n/a | $3.13 | - | 2 | May 2, 2018 | |
| CTMX CytomX Therapeutics | Maintains: Buy | $34 → $40 | $3.64 | +998.90% | 2 | Mar 8, 2018 | |
| PBYI Puma Biotechnology | Maintains: Buy | $135 → $115 | $6.81 | +1,588.69% | 2 | Jan 24, 2018 | |
| IRWD Ironwood Pharmaceuticals | Downgrades: Underperform | n/a | $3.67 | - | 4 | Jan 5, 2018 | |
| BIIB Biogen | Maintains: Buy | $358 → $365 | $190.56 | +91.54% | 1 | Oct 18, 2017 | |
| BOLD Boundless Bio | Maintains: Buy | $23 → $33 | $1.40 | +2,257.14% | 1 | Sep 22, 2017 | |
| AMGN Amgen | Upgrades: Buy | n/a | $330.75 | - | 1 | Feb 1, 2017 |
Vertex Pharmaceuticals
Mar 10, 2026
Maintains: Buy
Price Target: $571 → $598
Current: $434.31
Upside: +37.69%
Gilead Sciences
Feb 5, 2020
Maintains: Neutral
Price Target: $70 → $72
Current: $130.50
Upside: -44.83%
REGENXBIO
Jul 23, 2018
Downgrades: Neutral
Price Target: $64 → $80
Current: $5.66
Upside: +1,313.43%
Esperion Therapeutics
May 2, 2018
Downgrades: Underperform
Price Target: n/a
Current: $3.13
Upside: -
CytomX Therapeutics
Mar 8, 2018
Maintains: Buy
Price Target: $34 → $40
Current: $3.64
Upside: +998.90%
Puma Biotechnology
Jan 24, 2018
Maintains: Buy
Price Target: $135 → $115
Current: $6.81
Upside: +1,588.69%
Ironwood Pharmaceuticals
Jan 5, 2018
Downgrades: Underperform
Price Target: n/a
Current: $3.67
Upside: -
Biogen
Oct 18, 2017
Maintains: Buy
Price Target: $358 → $365
Current: $190.56
Upside: +91.54%
Boundless Bio
Sep 22, 2017
Maintains: Buy
Price Target: $23 → $33
Current: $1.40
Upside: +2,257.14%
Amgen
Feb 1, 2017
Upgrades: Buy
Price Target: n/a
Current: $330.75
Upside: -